Adenovirus
Conditions
Keywords
children, adenovirus, fever, betamethasone
Brief summary
The goal of this double-blind, Placebo-controlled Randomized Study is to assess if a single dose of betamethasone in children with febrile adenoviral infection works well in achieving an early fever regulation. The experimentation is conducted to answer this question: Can betamethasone help reduce fever more quickly in a child with viral adenovirus infection? The secondary objective is to assess if the child's overall clinical conditions improve more rapidly (reduced sore throat, quicker return to regular eating) and a reduction in the incidence and duration of hospitalizations.
Detailed description
Adenovirus pharyngitis is a highly febrile illness and tends to last for up to 5-7 days if treated only with antipyretics. Currently, there are no evidence-based effective treatments for this infection. The use of single-dose betamethasone is believed to be effective in significantly reducing the hyper-inflammation that the virus can induce in pediatric patients. However, it is an empirical therapeutic practice used variably because positive clinical experience encourages its prescription but lacks experimental evidence. The main question at hand is whether the single administration of betamethasone at a dosage of 0.1 mg/kg is truly effective in symptomatic adenoviral infection and whether it can, therefore, reduce the overall fever duration and improve the clinical condition of the children. The study does not involve changes to current clinical practice but aims to demonstrate that this clinical practice, mostly used empirically, is actually based on scientific evidence.
Interventions
DRUGBentelan
The experimental treatment group will be administered betamethasone 0.1 mg per kg.
DRUGPlacebo
The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
Sponsors
A.O.U. Città della Salute e della Scienza
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The nurse that will prepare and administer the treatment to the patient won't be masked
Intervention model description
A double-blind, placebo-controlled randomized study
Eligibility
Sex/Gender
ALL
Age
6 Months to 6 Years
Healthy volunteers
No
Inclusion criteria
* Body Temperature measured with an axillary or ear thermometer \>= n 37.5°C, persisting for a minimum of 6 hours and a maximum of 5 days. * Clinical presentation consistent with pharyngo-tonsillar infection by Adenovirus, including At least one of the following symptoms: pharyngodonidae /asthenia/nausea/vomiting/diarrhea/cough/rhinorrhea/abdominal pain/otalgia and at least one of the following signs: pharyngeal hyperemia with or without pharyngo-tonsillar exudate/inflammation of the upper or lower airways/lymphadenopathy/skin rash.- * Positive result on the antigen test for Adenovirus performed with the Biosensor rapid swab. * Negative result on the swab for Group A Streptococcus (SBEGA), if deemed necessary following McIsaac criteria * Informed consent form for participation in the study signed by the parent(s) or legal guardian.
Exclusion criteria
* Adequate dosage of betamethasone in the 48 hours prior. * Underlying chronic illness associated with an increased risk of unusual or severe adenoviral infection. * Inability to tolerate oral medications. * Documented allergy or any other known contraindication to Bentelan 0.5mg® medication.-Patients on chronic therapy with anticholinesterases, salicylates, nonsteroidal anti-inflammatory drugs, thiazides, furosemide, amphotericin, xanthines (theophylline), antidiabetic drugs, insulin, cyclosporine, ritonavir, ketoconazole, acetylsalicylic acid, phenytoin, phenobarbital, ephedrine, rifampicin, anticoagulants. * Subacute or chronic conditions requiring a higher equivalent dose of betamethasone or known primary or secondary adrenal insufficiency. * Transfer to another hospital for any reason. * Parents who are unable to understand the proposed study or cannot reliably participate in phone follow-up due to significant language barriers. * Participation in another study involving an experimental drug within the 30 days prior to and during the current study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with a sustained fever resolution at 24 hours from randomization | at 18 and 24 hours from randomization | The proportion of patients achieving sustained fever resolution at 24 hours from is the proportion of patients with a a body temperature \<37.5°C at 18 and 24 hours from randomization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalization | from date of randomization until the date of discharge from emergency department, up to 72 hours | The proportion of patients admitted following emergency access. |
| Duration of hospitalization (among those hospitalized), measured in days | from date of randomization until the date of discharge,up to 72 hours | Number of days from admission date to discharge date. |
| Pharyngeal-tonsillar pain level in patients younger than 36 months | from the date of randomization, up to 72 hours | According to the patient age, the pharyngeal-tonsillar pain level of the child will be measured by the FLACC (Face, Legs, Activity, Cry, Consolability) scale in patients younger than 36 months. FLACC mean value 5 points on ten. |
| Fever duration | from date of randomization until 72 hours from randomization | Time from randomization until the first measurement with Body Temperature\<37.5°C |
| Pharyngeal-tonsillar pain level in patients older than 36 months | from the date of randomization, up to 72 hours | According to the patient's age, the pharyngeal-tonsillar pain level of the child was measured by the Faces Pain Rating Scale (Wong-Baker Scale) in patients with age more or equal to 36 months. |
| Cumulative incidence of fever resolution | from date of randomization to 72 hours from randomization | Cumulative incidence of fever resolution is measured from randomization until the fever resolution confirmed by measurement at the subsequent timepoint; patients without fever resolution within the time of the last fever assessment are censored at this time. |
Countries
Italy
Contacts
Primary ContactClaudia Bondone, MD
Outcome results
None listed